FDA 483 - Unknown Company - November 15, 2016
Discuss this record with AI
This FDA Form 483 document details observations made during an inspection of a facility. The inspection revealed three key violations related to quality control, process validation, and record-keeping.
Observation 1 indicates that the firm failed to establish an adequate quality control unit. This suggests a systemic issue with the oversight and management of quality processes within the operation.
Observation 2 highlights that the manufacturing process for Product X was not adequately validated. This is a critical finding as it implies that the firm cannot assure that the manufacturing process consistently produces a product meeting its predetermined specifications and quality attributes. This could have significant business and operational implications, potentially leading to product recalls or regulatory actions.
Observation 3 notes that the firm did not maintain proper records of equipment cleaning and maintenance. This deficiency in record-keeping is crucial for demonstrating that equipment is suitable for its intended use and that cross-contamination risks are mitigated.
Collectively, these observations point to deficiencies in the firm's quality system and manufacturing practices, requiring corrective actions to ensure compliance with regulatory requirements.
- Inspection Date
- November 15, 2016
- Product Type
- Drugs
ID · c730653e-e0a4-4702-aa6d-f27219ee0c0b